Participation of p53 protein in the cellular response to DNA damage.

The inhibition of replicative DNA synthesis that follows DNA damage may be critical for avoiding genetic lesions that could contribute to cellular transformation. Exposure of ML-1 myeloblastic leukemia cells to nonlethal doses of the DNA damaging agents, gamma-irradiation or actinomycin D, causes a transient inhibition of replicative DNA synthesis via both G1 and G2 arrests. Levels of p53 protein in ML-1 cells and in proliferating normal bone marrow myeloid progenitor cells increase and decrease in temporal association with the G1 arrest. In contrast, the S-phase arrest of ML-1 cells caused by exposure to the anti-metabolite, cytosine arabinoside, which does not directly damage DNA, is not associated with a significant change in p53 protein levels. Caffeine treatment blocks both the G1 arrest and the induction of p53 protein after gamma-irradiation, thus suggesting that blocking the induction of p53 protein may contribute to the previously observed effects of caffeine on cell cycle changes after DNA damage. Unlike ML-1 cells and normal bone marrow myeloid progenitor cells, hematopoietic cells that either lack p53 gene expression or overexpress a mutant form of the p53 gene do not exhibit a G1 arrest after gamma-irradiation; however, the G2 arrest is unaffected by the status of the p53 gene. These results suggest a role for the wild-type p53 protein in the inhibition of DNA synthesis that follows DNA damage and thus suggest a new mechanism for how the loss of wild-type p53 might contribute to tumorigenesis.

[1]  L. R. Gurley,et al.  Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. , 1974, Biophysical journal.

[2]  N. Cozzarelli,et al.  Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine , 1976, Nature.

[3]  R. W. Jones,et al.  The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. , 1977, Radiation research.

[4]  M. Kastan,et al.  Distribution of repair-incorporated nucleotides and nucleosome rearrangement in the chromatin of normal and xeroderma pigmentosum human fibroblasts. , 1979, Biochemistry.

[5]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[6]  R. Painter,et al.  Radiosensitivity in ataxia-telangiectasia: a new explanation. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Doll,et al.  The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. , 1981, Journal of the National Cancer Institute.

[8]  A. Levine,et al.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells , 1981, Molecular and cellular biology.

[9]  J. Fraumeni,et al.  Prospective study of a family cancer syndrome. , 1982, JAMA.

[10]  A. Pardee,et al.  Mechanism by which caffeine potentiates lethality of nitrogen mustard. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[12]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[13]  A. Levine,et al.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 , 1983, Molecular and cellular biology.

[14]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[15]  R. Craig,et al.  Macromolecular and cell cycle effects of different classes of agents inducing the maturation of human myeloblastic leukemia (ML-1) cells. , 1984, Cancer research.

[16]  J. Jenkins,et al.  Precise epitope mapping of the murine transformation‐associated protein, p53. , 1985, The EMBO journal.

[17]  M. Oren,et al.  p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors , 1985, Molecular and cellular biology.

[18]  J. Yunis Genes and chromosomes in human cancer. , 1985, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

[19]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. E. Sippel,et al.  Subnuclear localization of proteins encoded by the oncogene v-myb and its cellular homolog c-myb , 1986, Molecular and cellular biology.

[21]  J. Denekamp,et al.  Cell kinetics and radiation biology. , 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[22]  M. Oren,et al.  Oligomerization of oncoprotein p53 , 1988, Journal of virology.

[23]  L. Hartwell,et al.  The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. , 1988, Science.

[24]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[25]  M. Muller,et al.  Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Schimke,et al.  Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. , 1989, Cytometry.

[27]  J. Chirgwin,et al.  Isolation of RNA. , 1989, Methods in enzymology.

[28]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[29]  M. Kastan,et al.  Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. , 1989, Blood.

[30]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Slamon,et al.  Expression of protooncogene c-myb in normal human hematopoietic cells. , 1989, Blood.

[32]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[33]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[34]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[35]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Vogelstein A deadly inheritance , 1990, Nature.

[37]  L. Strong,et al.  Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. , 1990, Cancer research.

[38]  J. Milner,et al.  p53 is associated with p34cdc2 in transformed cells. , 1990, The EMBO journal.

[39]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[40]  A. Balmain,et al.  Genetic changes in skin tumor progression: Correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7 , 1990, Cell.

[41]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Lock,et al.  Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. , 1990, Cancer research.

[43]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[44]  K. Kohn,et al.  Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. , 1990, Molecular pharmacology.

[45]  L. Hartwell,et al.  Characterization of RAD9 of Saccharomyces cerevisiae and evidence that its function acts posttranslationally in cell cycle arrest after DNA damage , 1990, Molecular and cellular biology.

[46]  L. Ellwein,et al.  Cell proliferation in carcinogenesis. , 1990, Science.

[47]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[48]  A. Levine,et al.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. , 1991, Genes & development.

[49]  C. Marshall Tumor suppressor genes , 1991, Cell.

[50]  C. Wolkow,et al.  Levels of p53 protein increase with maturation in human hematopoietic cells. , 1991, Cancer research.

[51]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[52]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.